Canaccord Genuity Group Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Posted by Brian Himes on May 19th, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective dropped by research analysts at Canaccord Genuity Group from $1,057.00 to $875.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Canaccord Genuity Group’s target price points to a potential upside of 39.24% from the company’s current price.

Several other brokerages have also commented on REGN. Royal Bank Of Canada dropped their price target on Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating for the company in a research note on Monday. Evercore increased their target price on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research report on Thursday, January 22nd. Oppenheimer reaffirmed an “outperform” rating and set a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. BMO Capital Markets decreased their price objective on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research note on Monday. Finally, Barclays cut their target price on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $792.65.

View Our Latest Research Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Trading Down 0.2%

Shares of REGN traded down $1.29 during mid-day trading on Tuesday, hitting $628.39. The company had a trading volume of 59,424 shares, compared to its average volume of 769,293. Regeneron Pharmaceuticals has a 1-year low of $476.49 and a 1-year high of $821.11. The business’s 50-day simple moving average is $741.98 and its 200-day simple moving average is $745.92. The stock has a market cap of $66.43 billion, a PE ratio of 15.28, a P/E/G ratio of 1.55 and a beta of 0.30. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last posted its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. During the same quarter last year, the firm posted $8.22 earnings per share. Regeneron Pharmaceuticals’s revenue was up 19.0% on a year-over-year basis. Sell-side analysts forecast that Regeneron Pharmaceuticals will post 37.1 earnings per share for the current year.

Insider Activity

In other news, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the sale, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. The trade was a 49.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the transaction, the director owned 17,503 shares in the company, valued at approximately $12,343,815.72. This trade represents a 0.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by company insiders.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Sound Shore Management Inc CT bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $64,677,000. Rakuten Investment Management Inc. bought a new position in Regeneron Pharmaceuticals in the third quarter worth about $33,121,000. Ellerson Group Inc. ADV boosted its stake in Regeneron Pharmaceuticals by 49.2% in the third quarter. Ellerson Group Inc. ADV now owns 8,102 shares of the biopharmaceutical company’s stock valued at $4,556,000 after acquiring an additional 2,671 shares during the period. Nordea Investment Management AB grew its holdings in shares of Regeneron Pharmaceuticals by 118.1% during the fourth quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock valued at $105,810,000 after purchasing an additional 74,350 shares during the last quarter. Finally, Oppenheimer & Co. Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 7.2% during the third quarter. Oppenheimer & Co. Inc. now owns 23,714 shares of the biopharmaceutical company’s stock valued at $13,334,000 after purchasing an additional 1,597 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Negative Sentiment: Regeneron’s Phase 3 melanoma study of fianlimab + Libtayo failed to meet its primary endpoint versus Merck’s Keytruda, raising concerns about the company’s ability to compete in a key cancer market and triggering a sharp selloff. Article Title
Negative Sentiment: Multiple law firms launched shareholder and securities-law investigations after the trial miss, with claims that executives were overly optimistic before the disappointing results were disclosed. Article Title
Negative Sentiment: Several Wall Street firms cut price targets or downgraded the stock following the data release, including Citigroup, Wells Fargo, JPMorgan, RBC, Truist, Piper Sandler, BMO, and Leerink, signaling reduced near-term confidence. Article Title
Positive Sentiment: Regeneron announced a strategic collaboration with Parabilis Medicines to develop novel Antibody-Helicon™ Conjugates, a potentially meaningful pipeline expansion that includes $125 million upfront and up to about $2.2 billion in milestone payments. Article Title
Neutral Sentiment: Despite the negative news flow, some analysts kept constructive ratings or still see upside to current levels, suggesting the selloff may be driven more by the clinical setback than by a broader deterioration in Regeneron’s core business. Article Title

About Regeneron Pharmaceuticals

(Get Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.